Dear Colleagues,

Flow cytometry has evolved over the years into an independent research field that investigates the quantification of the cellular phenotype. Cancer is among the leading causes of human mortality, in which neoplastic cells form a tumor that may invade adjacent tissue or metastasize to distant organs. Given the complex nature of cancer, novel approaches are always focused on the need for the accurate characterization of cancer cells and the design of effective treatment. The applications of flow cytometry on cancer extend, among others, from diagnosis of hematological malignancies and the interplay between the immune system and cancer to the study of the tumor phenotype, heterogeneity, and the intraoperative tumor diagnosis and prognosis.

Recent advances in the field include technological innovations such as mass cytometry, spectral cytometry, and imaging cytometry, as well as methodological innovations in acquisition and analysis, such as the of application of machine learning and artificial intelligence algorithms. These advances have rendered flow cytometry an invaluable tool in the fields of basic and translational cancer research.

The aim of the current Special Issue, “Flow Cytometry in Cancer Research”, is to define the state-of-the-art in the field as well as to present recent flow cytometry innovations with an application in cancer research. We wish to serve as a forum for researchers applying flow cytometry in oncology, leading to knowledge dissemination in the fight against this devastating disease.

We are welcoming primary or review articles covering, but not limited to, the following topics:

• Reviews describing the state-of-the-art in the field;
• The contribution of cytometry in basic and translational cancer research;
• Novel methodologies for phenotypic analysis of cancer;
• Clinical or animal models that incorporate flow cytometry analyses;
• Technological and methodological advances of diagnostic techniques (for example, multiparametric analysis in hematology, oncology, immunology, etc.).

Dr. George Vartholomatos
Dr. Lefkothea Dova
Dr. Georgios S. Markopoulos
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• flow cytometry
• translational oncology
• cancer research
• oncology
• hematology
• immunology